TIME COURSE OF CHANGES IN LABORATORY BIOMARKERS IN PATIENTS WITH RHEUMATOID ARTHRITIS DURING TOCILIZUMAB THERAPY

TIME COURSE OF CHANGES IN LABORATORY BIOMARKERS IN PATIENTS WITH RHEUMATOID ARTHRITIS DURING TOCILIZUMAB THERAPY

Objective: to study the time course of changes in laboratory biomarkers in patients with rheumatoid arthritis (RA) 2, 4, and 8 weeks after the initiation of tocilizumab (TCZ) therapy. Subjects and methods. Forty-two RA patients receiving two intravenous infusions of TCZ (8 mg/kg each) at a 4-week in...

Πλήρης περιγραφή

Λεπτομέρειες βιβλιογραφικής εγγραφής
Κύριοι συγγραφείς:	E N Aleksandrova, E Yu Panasyuk, A S Avdeyeva, A A Novikov, G V Lukina, M V Cherkasova, N V Klimova, E L Nasonov
Μορφή:	Άρθρο
Γλώσσα:	Russian
Έκδοση:	IMA PRESS LLC 2011-06-01
Σειρά:	Научно-практическая ревматология
Θέματα:	rheumatoid arthritis, interleukin-6 interleukin-6 receptors tocilizumab, erythrocyte sedimentation rate c-reactive protein, igm/iga rheumatoid factor anti-cyclic citrullinated peptide antibodies anti-modified citrullinated vimentin antibodies
Διαθέσιμο Online:	https://rsp.mediar-press.net/rsp/article/view/705

Παρόμοια τεκμήρια

Impact of tocilizumab therapy on immunological parameters in patients with rheumatoid arthritis
ανά: Anastasia Sergeyevna Avdeyeva, κ.ά.
Έκδοση: (2012-06-01)

Bone destruction in rheumatoid arthritis: role of autoantibodies
ανά: Anastasia Sergeyevna Avdeyeva, κ.ά.
Έκδοση: (2013-06-01)

THE CLINICAL AND IMMUNOLOGICAL EFFECTS OF ANTI-B-CELL THERAPY IN PATIENTS WITH RHEUMATOID ARTHRITIS
ανά: Elena Nikolayevna Aleksandrova, κ.ά.
Έκδοση: (2012-02-01)

DIAGNOSTIC MARKERS AND CYTOKINE PROFILE IN PATIENTS WITH RHEUMATOID ARTHRITIS RECEIVING DMARDS
ανά: Maria Sergeevna Voronina, κ.ά.
Έκδοση: (2012-10-01)

Anti-modified citrullinated vimentin antibody: a novel biomarker associated with cardiac systolic dysfunction in patients with rheumatoid arthritis
ανά: Somayye Norouzi, κ.ά.
Έκδοση: (2020-08-01)

New approaches to pharmacotherapy for rheumatoid arthritis: perspective for use of tocilizumab (monoclonal antibodies to interleukin-6 receptor)
ανά: Evgeniy L'vovich Nasonov, κ.ά.
Έκδοση: (2010-05-01)

Correlation between anti-mutated citrullinated vimentin and bone turnover markers (CTX-1 and P1NP) in patients with rheumatoid arthritis in remission and low-disease activity
ανά: Tulus Widiyanto, κ.ά.
Έκδοση: (2022-08-01)

Methotrexate-induced changes in the concentration of antibodies to modified citrulnated vimentin in blood serum of patients with rheumatoid arthritis
ανά: Natal'ya Petrovna Shilkina, κ.ά.
Έκδοση: (2011-05-01)

Serum sirtuin-1 a potential marker in the diagnosis of rheumatoid arthritis
ανά: Liming Tan, κ.ά.
Έκδοση: (2023-12-01)

Specificity of Anti-Citrullinated Protein Antibodies in Rheumatoid Arthritis
ανά: Nicole H. Trier, κ.ά.
Έκδοση: (2019-06-01)

Assessment of the Correlation between Disease Activity and Serum Biomarker Anti-MCV and IL6 in Iraqi Patients with Rheumatoid Arthritis
ανά: Dania A. Ali, κ.ά.
Έκδοση: (2024-10-01)

Rheumatoid factor and antibodies against cyclic citrullinated peptide in patients without rheumatoid arthritis
ανά: N. V. Bunchuk
Έκδοση: (2023-01-01)

Antibodies to cyclic citrullinized peptide in rheumatoid arthritis
ανά: E N Aleksandrova, κ.ά.
Έκδοση: (2004-12-01)

Epitope Specificity of Anti-Citrullinated Protein Antibodies
ανά: Nicole H. Trier, κ.ά.
Έκδοση: (2017-03-01)

Identification of anti-citrullinated osteopontin antibodies and increased inflammatory response by enhancement of osteopontin binding to fibroblast-like synoviocytes in rheumatoid arthritis
ανά: Akio Umemoto, κ.ά.
Έκδοση: (2023-02-01)

The roles of anti-citrullinated protein antibodies in the immunopathogenesis of rheumatoid arthritis
ανά: Hui-Chun Yu, κ.ά.
Έκδοση: (2019-01-01)

Specificity of Anti-Citrullinated Protein Antibodies to Citrullinated α-Enolase Peptides as a Function of Epitope Structure and Composition
ανά: Ilaria Fanelli, κ.ά.
Έκδοση: (2021-07-01)

Antibodies against citrullinated proteins in relation to periodontitis with or without rheumatoid arthritis: a cross-sectional study
ανά: Pit Hui Lew, κ.ά.
Έκδοση: (2021-07-01)

Different clinical relevance of anti-citrullinated proteins antibodies in RA patients
ανά: A. S. Avdeeva, κ.ά.
Έκδοση: (2022-05-01)

INHIBITION OF INTERLEUKIN 6 IN IMMUNE INFLAMMATORY RHEUMATIC DISEASES: ACHIEVEMENTS, PROSPECTS, AND HOPES
ανά: E. L. Nasonov, κ.ά.
Έκδοση: (2018-01-01)

Tocilizumab (Actemra)
ανά: Martin Sheppard, κ.ά.
Έκδοση: (2017-09-01)

Abatacept reduces disease activity of rheumatoid arthritis independently of modulating anti-citrullinated peptide antibody production
ανά: Hisakata Yamada, κ.ά.
Έκδοση: (2020-04-01)

Evaluation of anti-mutated citrullinated vimentin antibodies, anti-cyclic citrullinated peptide antibodies in patients with rheumatoid arthritis in comparison with other rheumatic diseases; a nephrology point of view
ανά: Alireza Sadeghi, κ.ά.
Έκδοση: (2017-04-01)

Type-III interferons and rheumatoid arthritis: Correlation between interferon lambda 1 (interleukin 29) and antimutated citrullinated vimentin antibody levels
ανά: Diana Castillo-Martínez, κ.ά.
Έκδοση: (2017-02-01)

Anti-cyclic citrullinated peptide antibodies and rheumatoid factor in leprosy patients with articular involvement
ανά: S.L.E. Ribeiro, κ.ά.
Έκδοση: (2008-11-01)

RHEUMATOID FACTOR AND ANTI-CYCLIC CITRULLINATED PEPTIDE ANTIBODIES IN PATIENTS WITH PSORIATIC ARTHRITIS
ανά: V. V. Badokin, κ.ά.
Έκδοση: (2011-06-01)

When Autoantibodies Are Missing: The Challenge of Seronegative Rheumatoid Arthritis
ανά: Marino Paroli, κ.ά.
Έκδοση: (2023-10-01)

The diagnostic value of anti-cyclic citrullinated peptide antibodies (anti-CCP) in patients with rheumatoid arthritis
ανά: Damjanovska Ljubinka, κ.ά.
Έκδοση: (2007-01-01)

INVESTIGATION OF CANDIDATE GENE POLYMORPHISMS IN AN IMMUNE RESPONSE AS MARKERS FOR THE RISK OF DEVELOPING RHEUMATOID ARTHRITIS AND PRODUCING AUTOANTIBODIES
ανά: I. A. Guseva, κ.ά.
Έκδοση: (2016-03-01)

THE 2016 EULAR GUIDELINES FOR THE DIAGNOSIS AND TREATMENT OF EARLY ARTHRITIS
ανά: E. L. Nasonov
Έκδοση: (2017-04-01)

The clinical aspect of overweight on rheumatoid arthritis and disease activity
ανά: Haitham Ahmed, κ.ά.
Έκδοση: (2019-06-01)

Evaluation of a new biomarker 14-3-3 Eta protein in diagnosis of rheumatoid arthritis
ανά: Lakshmi Deepika Yarlagadda, κ.ά.
Έκδοση: (2020-01-01)

Asthma and elevation of anti-citrullinated protein antibodies prior to the onset of rheumatoid arthritis
ανά: Alessandra Zaccardelli, κ.ά.
Έκδοση: (2019-11-01)

Cerebrovascular reactivity depending on rheumatoid factor and anticitrullinated protein antibody positivity in hypertensive patients with rheumatoid arthritis
ανά: N. V. Rebrova, κ.ά.
Έκδοση: (2022-07-01)

RAPID EFFECT OF TOCILIZUMAB IN RHEUMATOID ARTHRITIS
ανά: E Yu Panasyuk, κ.ά.
Έκδοση: (2011-08-01)

THE CLINICAL AND DIAGNOSTIC VALUE OF ANTI-CYCLIC CITRULLINATED PEPTIDE ANTIBODIES IN EARLY JUVENILEARTHRITIS
ανά: S O Salugina, κ.ά.
Έκδοση: (2009-06-01)

Multicenter, observational clinical study of abatacept in Japanese patients with rheumatoid arthritis
ανά: Noriyoshi Ogawa, κ.ά.
Έκδοση: (2019-01-01)

The diagnostic value of anti-cyclic citrullinated peptide antibodies, adenosine deaminase activity and other potential biomarkers for predicting and monitoring rheumatoid arthritis
ανά: Mehanović-Nikolić Jasminka, κ.ά.
Έκδοση: (2008-01-01)

An assessment of anti-citrullinated protein antibody in systemically healthy individuals with or without chronic periodontitis: A case–control study
ανά: Ankita Rajaram Yadav, κ.ά.
Έκδοση: (2020-01-01)

DIAGNOSTIC VALUE OF ANTI-PEPTIDYLARGININE DEIMINASE TYPE 4 (PADI-4) AND ANTI- CITRULLINATED PEPTIDE ANTIBODIES (ACCP) IN IRAQI PATIENTS WITH RHEUMATOID ARTHRITIS
ανά: Hassan J Hasony, κ.ά.
Έκδοση: (2014-06-01)